Since resistin release is stimulated by pro-inflammatory cytokines and vice versa, and primarily produced by PBMCs in humans, increased resistin production by PBMCs of MS patients could be an important driver of chronic inflammation. The gene discussed is RETN; the disease is myeloid sarcoma.